Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a ‘Hold’ rating from Wells Fargo, which set the company’s stock price ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently conducted its Annual General Meeting, resulting in approved changes to its company bylaws. The amendments, along with the promising results from the ...

While the introduction of a dividend this year feels like a concession to investors on the back of a dismal Q4 for its share price, it also may mark the moment Regeneron fully joined the "Big ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo. The company also announced a dividend for the first time.

Looking at the universe of stocks we cover at Dividend Channel, on 5/20/25, Regeneron Pharmaceuticals, Inc. (Symbol: REGN), PROG Holdings Inc (Symbol: PRG), and Prudential Financial Inc (Symbol ...

The S&P 500 rebounded in May, but some stocks crashed on company-specific concerns. While one healthcare giant withdrew its ...

Regeneron initiated a quarterly dividend per share that looks somewhat attractive. Despite some recent issues, the biotech company's business remains solid. Regeneron's share repurchase program ...

Shares are trading up in response to better-than-expected results and initiation of quarterly dividend program. Regeneron’s shares have lost 28.8% in the past year compared with the industry’s ...

It also declared a quarterly dividend and continues share buybacks, with $3.874 billion in repurchase capacity remaining. REGN Price Action: Regeneron shares were up 5.43% at $599.65 at the time ...

Regeneron Pharmaceuticals (REGN.O), opens new tab beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and ...